Dr. Kunz on the Impact of Lanreotide’s Approval for Neuroendocrine Tumors
1 Views
administrator
07/13/23
Pamela L. Kunz, MD, assistant professor, Division of Oncology, Stanford University School of Medicine, discusses the impact of the approval of lanreotide.
-
Category
Show more
Facebook Comments
No comments found